ArticleGut pathogens2026
Inhibitory effect of Acetylshikonin on drug-resistant Candida albicans.
Article in Gut pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCandida albicans (C. albicans) is among the most common opportunistic fungal pathogens and causes superficial infections and life-threatening invasive candidiasis in immunocompromised individuals. In recent years, C. albicans has become resistant to a wide range of clinical drugs, and the identification of effective antifungal drugs is an extremely urgent medical need. Acetylshikonin (ASK) is a naphthoquinone compound extracted from Lithospermum erythrorhizon that exhibits potent antibacterial activity. However, its efficacy against C. albicans and antimicrobial mechanisms, especially against drug-resistant C. albicans, are unclear. MATERIALS AND
methodsThe antifungal activity of ASK was evaluated based on minimal inhibitory concentration (MIC) and minimal fungicidal concentration (MFC) measured in vitro and in mouse models of vulvovaginal candidiasis and oropharyngeal candidiasis to assess its efficacy in vivo. Mechanistic investigations included assessments of cell membrane and cell wall damage, adhesion ability, oxidative stress evaluation, protein expression, and target identification (including RT‒qPCR, molecular docking, and related methods).
resultsThe main active ingredient from Lithospermum erythrorhizon that targets C. albicans was identified as ASK. It exhibits significant activity against drug-resistant fungi both in vitro and in vivo. Moreover, ASK can reduce the adhesion of C. albicans and damage to cell membrane and cell wall and induce apoptosis-like cell death-like cell death. In addition, ASK may directly bind to Malate Synthase 1 (Mls1) and effectively downregulate its expression and inhibit the glyoxylate cycle, leading to the generation and accumulation of large amounts of ROS, and damage to DNA to achieve its antifungal effects.
conclusionASK can treatment drug-resistant C. albicans infections, its mechanism of action is related to the inhibition of Mls1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.